CN102924424B - Method for synthesizing doxepin hydrochloride - Google Patents
Method for synthesizing doxepin hydrochloride Download PDFInfo
- Publication number
- CN102924424B CN102924424B CN201210388828.XA CN201210388828A CN102924424B CN 102924424 B CN102924424 B CN 102924424B CN 201210388828 A CN201210388828 A CN 201210388828A CN 102924424 B CN102924424 B CN 102924424B
- Authority
- CN
- China
- Prior art keywords
- doxepin
- reaction
- hydrochloric acid
- concentrated hydrochloric
- described step
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MHNSPTUQQIYJOT-SJDTYFKWSA-N Doxepin Hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 MHNSPTUQQIYJOT-SJDTYFKWSA-N 0.000 title claims abstract description 24
- 229960002861 doxepin hydrochloride Drugs 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 13
- 230000002194 synthesizing effect Effects 0.000 title abstract description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 87
- 238000006243 chemical reaction Methods 0.000 claims abstract description 47
- 229960005426 doxepin Drugs 0.000 claims abstract description 33
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims abstract description 33
- 239000003054 catalyst Substances 0.000 claims abstract description 30
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims abstract description 24
- -1 olefin compounds Chemical class 0.000 claims abstract description 19
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000007259 addition reaction Methods 0.000 claims abstract description 10
- 239000007810 chemical reaction solvent Substances 0.000 claims abstract description 9
- 238000005859 coupling reaction Methods 0.000 claims abstract description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 48
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 20
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
- 230000035484 reaction time Effects 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 12
- WHVMPBIIYDTYRE-UHFFFAOYSA-N 2-(3-chloropropoxy)-2-methylpropane Chemical compound CC(C)(C)OCCCCl WHVMPBIIYDTYRE-UHFFFAOYSA-N 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 2
- 239000012467 final product Substances 0.000 claims 1
- YUSHFLBKQQILNV-UHFFFAOYSA-N 6h-benzo[c][1]benzoxepin-11-one Chemical compound C1OC2=CC=CC=C2C(=O)C2=CC=CC=C21 YUSHFLBKQQILNV-UHFFFAOYSA-N 0.000 abstract description 19
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 150000001298 alcohols Chemical class 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 229910052801 chlorine Inorganic materials 0.000 abstract description 5
- 239000000460 chlorine Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 239000000047 product Substances 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 10
- 238000000921 elemental analysis Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 10
- 239000012043 crude product Substances 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 150000003997 cyclic ketones Chemical class 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007809 chemical reaction catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种合成盐酸多塞平的方法,包括如下步骤:1、将6,11-二氢二苯并[b,e]噁庚英-11-酮和3-氯丙基-叔丁基醚进行加成反应得醇类化合物;2、所述醇类化合物在浓盐酸条件下消去羟基得到烯烃类化合物;3、所述烯烃类化合物在反应溶剂中与二氯亚砜反应得到氯代物;4、所述氯代物和N,N-二甲基甲胺偶联得到多塞平;5、将多塞平制成其盐酸盐,即得。本发明在第4步C-N偶联反应中创造性地使用Ni(OAc)2/PPh3体系,反应选择性好、收率高、对环境友好,而且催化剂经简单过滤可循环使用多次,极大的降低了生产成本。整个合成工艺操作简单,原料易得,成本低廉,符合工业化生产要求,有望得到工业化应用。The invention provides a method for synthesizing doxepin hydrochloride, comprising the following steps: 1. 6,11-dihydrodibenzo[b,e]oxepin-11-one and 3-chloropropyl-tert Addition reaction of butyl ether to obtain alcohol compounds; 2, the alcohol compounds eliminate hydroxyl groups under concentrated hydrochloric acid conditions to obtain olefin compounds; 3, the olefin compounds react with thionyl chloride in the reaction solvent to obtain chlorine 4. The chlorinated compound is coupled with N,N-dimethylmethylamine to obtain doxepin; 5. Doxepin is made into its hydrochloride, to obtain. The present invention creatively uses the Ni(OAc) 2 /PPh 3 system in the CN coupling reaction of the fourth step, which has good reaction selectivity, high yield, and is environmentally friendly, and the catalyst can be recycled for many times through simple filtration, greatly reduced production costs. The whole synthesis process is simple to operate, the raw materials are easy to obtain, and the cost is low, which meets the requirements of industrial production and is expected to be applied in industrialization.
Description
技术领域 technical field
本发明属于化学合成领域,具体涉及一种合成盐酸多塞平的方法。 The invention belongs to the field of chemical synthesis, in particular to a method for synthesizing doxepin hydrochloride. the
背景技术 Background technique
盐酸多塞平(Doxepin Hydrochloride)是用于治疗抑郁症及焦虑性神经症的药,其作用在于抑制中枢神经系统对5-羟色胺及去甲肾上腺素的再摄取,从而使突触间隙中这二种神经递质浓度增高而发挥抗抑郁作用,也具有抗焦虑和镇静作用。盐酸多塞平口服吸收好,生物利用度为13-45%,半衰期(t1/2)为8-12小时,表观分布容积(Vd)9-33L/kg。主要在肝脏代谢,活性代谢产物为去甲基化物。代谢物自肾脏排泄,老年病人对本品的代谢和排泄能力下降。其化学名为N,N-二甲基-3-二苯并[b,e]-{恶}庚英-11(6H)亚基-1-丙胺盐酸盐顺反异构体混合物,CAS号:1229-29-4.盐酸多塞平的结构式如下: Doxepin Hydrochloride is a medicine used for the treatment of depression and anxiety neurosis. Its function is to inhibit the reuptake of 5-hydroxytryptamine and norepinephrine in the central nervous system, so that the two in the synaptic cleft It exerts antidepressant effects by increasing the concentration of this neurotransmitter, and also has anti-anxiety and sedative effects. Doxepin hydrochloride is well absorbed orally, with a bioavailability of 13-45%, a half-life (t1/2) of 8-12 hours, and an apparent volume of distribution (Vd) of 9-33L/kg. It is mainly metabolized in the liver, and the active metabolite is demethylation. The metabolites are excreted by the kidneys, and the ability to metabolize and excrete this product decreases in elderly patients. Its chemical name is N,N-dimethyl-3-dibenzo[b,e]-{oxa}heptin-11(6H)ylidene-1-propanamine hydrochloride cis-trans isomer mixture, CAS No.: 1229-29-4. The structural formula of doxepin hydrochloride is as follows:
至今为止关于盐酸多塞平的全合成有一些报道(如专利US20100179215,US20100179214,US20100305326)。其中涉及到第四部碳氮偶联的反应,大多数还是使用一些苛刻的操作条件或贵金属试剂,如Pd、Pt、Ru、Rh等。这里不仅涉及到催化剂成本高、操作繁琐等缺点外,还涉及到催化剂的循环使用及对环境的污染等问题。而这步偶联反应关系到整个盐酸多塞平的合成。在这种条件下开发出绿色环保、低成本无毒、可循环使用的催化剂就显得尤为重要。令人欣慰的是发明人意外发现Ni催化剂对于本步反应有奇特的效果,反应收率高,副产物少,关键催化剂价廉易得,可循环使用,因此,本发明将Ni(OAc)2/PPh3催化体系运用到盐酸多塞平的合成中。同时,对反应路线进行了整体的优化和改进,得到了一种理想的合成盐酸多塞平的方法。 So far, there are some reports on the total synthesis of doxepin hydrochloride (such as patents US20100179215, US20100179214, US20100305326). Most of the reactions involving the fourth carbon-nitrogen coupling still use some harsh operating conditions or noble metal reagents, such as Pd, Pt, Ru, Rh, etc. This not only involves the disadvantages of high catalyst cost and cumbersome operation, but also involves the recycling of the catalyst and the pollution to the environment. And this step coupling reaction is related to the synthesis of the whole doxepin hydrochloride. Under such conditions, it is particularly important to develop green, low-cost, non-toxic and recyclable catalysts. It is gratifying that the inventor unexpectedly found that the Ni catalyst has a peculiar effect on this step reaction, the reaction yield is high, the by-products are few, the key catalyst is cheap and easy to obtain, and can be recycled. Therefore, the present invention uses Ni(OAc) 2 /PPh 3 catalytic system applied to the synthesis of doxepin hydrochloride. At the same time, the overall optimization and improvement of the reaction route was carried out, and an ideal method for synthesizing doxepin hydrochloride was obtained.
发明内容 Contents of the invention
本发明的目的在于提供一种能够简单、绿色环保、整体收率高的合成盐酸多塞平的方法。 The object of the present invention is to provide a method for synthesizing doxepin hydrochloride which is simple, environmentally friendly and has a high overall yield. the
为实现发现目的,本发明采用如下技术方案: To realize the purpose of discovery, the present invention adopts the following technical solutions:
一种合成盐酸多塞平的方法,包括以下步骤: A method for synthesizing doxepin hydrochloride, comprising the following steps:
(1)6,11-二氢二苯并[b,e]噁庚英-11-酮和3-氯丙基-叔丁基醚进行加成反应得醇类化合物; (1) Addition reaction of 6,11-dihydrodibenzo[b,e]oxepin-11-one and 3-chloropropyl-tert-butyl ether to obtain alcohol compounds;
(2)所述醇类化合物在浓盐酸条件下消去羟基得到烯烃类化合物; (2) The alcohol compound is eliminated under the condition of concentrated hydrochloric acid to obtain the olefin compound;
(3)所述烯烃类化合物在反应溶剂中与二氯亚砜反应得到氯代物; (3) The olefinic compound reacts with thionyl chloride in the reaction solvent to obtain chlorinated compounds;
(4)所述氯代物和N,N-二甲基甲胺偶联得到多塞平; (4) The chlorinated compound is coupled with N,N-dimethylmethylamine to obtain doxepin;
(5)将多塞平制成其盐酸盐,即得。 (5) Make doxepin into its hydrochloride, that is. the
其中,本发明优选所述的步骤1为:用量比为1:1-1:1.5的6,11-二氢二苯并[b,e]噁庚英-11-酮和3-氯丙基-叔丁基醚在催化剂的作用下在无水乙醚中进行加成反应,反应回流得醇类化合物,更优选用量比为1:1.2。 Among them, the preferred step 1 of the present invention is: 6,11-dihydrodibenzo[b,e]oxepin-11-one and 3-chloropropyl with an amount ratio of 1:1-1:1.5 - The addition reaction of tert-butyl ether in anhydrous ether under the action of a catalyst, and the reaction is refluxed to obtain alcohol compounds, and the more preferred dosage ratio is 1:1.2. the
本发明说明书中,所述的6,11-二氢二苯并[b,e]噁庚英-11-酮(CAS:4504-87-4)即下文所述的环酮。 In the description of the present invention, the 6,11-dihydrodibenzo[b,e]oxepin-11-one (CAS: 4504-87-4) is the cyclic ketone described below. the
此外,步骤1中,无水乙醚作为溶剂滴加,其体积用量为6,11-二氢二苯并[b,e]噁庚英-11-酮重量的5.5-6.3倍,,所述的催化剂为镁粉,催化剂的投放量为6,11-二氢二苯并[b,e]噁庚英-11-酮的1.8-2.2倍,反应时间为2-5h,温度为35-40℃。 In addition, in step 1, anhydrous diethyl ether is added dropwise as a solvent, and its volumetric dosage is 5.5-6.3 times the weight of 6,11-dihydrodibenzo[b,e]oxepin-11-one, the The catalyst is magnesium powder, the dosage of the catalyst is 1.8-2.2 times that of 6,11-dihydrodibenzo[b,e]oxepin-11-one, the reaction time is 2-5h, and the temperature is 35-40℃ . the
本步骤中,无水乙醚的滴加速度为其用量的2%-6%每分钟,在该滴加速度下,6,11-二氢二苯并[b,e]噁庚英-11-酮和3-氯丙基-叔丁基醚能够实现更理想的加成反应。 In this step, the rate of addition of anhydrous ether is 2%-6% per minute of its consumption, and at this rate of addition, 6,11-dihydrodibenzo[b,e]oxepin-11-one and 3-Chloropropyl-tert-butyl ether can achieve a more ideal addition reaction. the
步骤2中醇类化合物在浓盐酸条件下保持沸腾,浓盐酸的用量为反应底物的2-10倍;反应时间为5-8h。 In step 2, the alcohol compound is kept boiling under concentrated hydrochloric acid, and the amount of concentrated hydrochloric acid is 2-10 times that of the reaction substrate; the reaction time is 5-8h. the
步骤3中反应溶剂为苯或甲苯,烯烃类化合物与二氯亚砜的用量比为1:1-1:1.5,,反应在110-120℃下加热回流2-4h,优选烯烃类化合物与二氯亚砜的用量比为1:1.2,反应在115℃下加热回流3h。 In step 3, the reaction solvent is benzene or toluene, the ratio of olefinic compound to thionyl chloride is 1:1-1:1.5, and the reaction is heated under reflux at 110-120°C for 2-4h, preferably olefinic compound and dichloride The dosage ratio of thionyl chloride was 1:1.2, and the reaction was heated to reflux at 115°C for 3h. the
步骤4以Ni(OAc)2作为反应催化剂,三苯基膦作为配体。 Step 4 uses Ni(OAc) 2 as the reaction catalyst and triphenylphosphine as the ligand.
本发明优选所述的步骤4具体为:在催化剂的作用下,氯代物和N,N-二甲基甲胺在DMF于35-45℃条件下反应4-6h,优选在40℃条件下反应5h,偶联得到多塞平。 The preferred step 4 of the present invention is specifically: under the action of a catalyst, the chloride and N,N-dimethylmethylamine are reacted in DMF at 35-45°C for 4-6h, preferably at 40°C 5h, coupled to get doxepin. the
该步骤4中,氯代物和N,N-二甲基甲胺的用量比为1:1-1:1.5,催化剂的投放量为2-8%,配体与氯代物的用量比为8:1-12:1,优选氯代物和N,N-二甲基甲胺的用量比为1:1.1,催化剂的投放量为5%,配体与氯代物的用量比为10:1。 In this step 4, the consumption ratio of chloride and N,N-dimethylmethylamine is 1:1-1:1.5, the dosage of catalyst is 2-8%, and the consumption ratio of ligand and chloride is 8: 1-12:1, preferably the ratio of chloride to N,N-dimethylmethylamine is 1:1.1, the dosage of catalyst is 5%, and the ratio of ligand to chloride is 10:1. the
此外,本发明所述的合成方法步骤1-4均还包括对各步骤所得产物粗品进行重结晶的操作,具体的重结晶为本领域技术人员所掌握,本发明优选采用石油醚对步骤1-4所得中间产物进行重结晶处理,使整个合成方法的产率及纯度进一步得到保障。 In addition, steps 1-4 of the synthesis method described in the present invention also include the operation of recrystallizing the crude product obtained in each step. The specific recrystallization is grasped by those skilled in the art. In the present invention, petroleum ether is preferably used for steps 1-4. 4. The obtained intermediate product is subjected to recrystallization treatment, so that the yield and purity of the whole synthesis method are further guaranteed. the
本发明优选所述的步骤5为:多塞平在浓盐酸中,以135-145°C反应15-18h得到盐酸多塞平,多塞平与浓盐酸的用量比为1:4-1:6,优选多塞平在浓盐酸中,以140℃反应16h得到盐酸多塞平,多塞平与浓盐酸的用量比为1:5。 Preferably described step 5 of the present invention is: doxepin is in concentrated hydrochloric acid, obtains doxepin hydrochloride with 135-145 ℃ of reaction 15-18h, and the consumption ratio of doxepin and concentrated hydrochloric acid is 1:4-1: 6. Preferably, doxepin is reacted in concentrated hydrochloric acid at 140°C for 16 hours to obtain doxepin hydrochloride, and the dosage ratio of doxepin to concentrated hydrochloric acid is 1:5. the
本发明所述的溶剂使用前都经过处理,除浓盐酸可直接使用外,其他溶剂使用前均经氢化钙干燥再减压蒸馏。 The solvents of the present invention are all processed before use, except that concentrated hydrochloric acid can be used directly, and other solvents are all dried with calcium hydride and then distilled under reduced pressure before use. the
本发明所用的盐酸为体积百分比浓度为35-40%,优选37%的浓盐酸。 The hydrochloric acid used in the present invention is that volume percent concentration is 35-40%, preferably the concentrated hydrochloric acid of 37%. the
整个反应路线见下所示: The whole reaction route is shown below:
采用上述技术方案,本发明具有如下有益效果: Adopt above-mentioned technical scheme, the present invention has following beneficial effect:
1、整个合成方法简单可控,反应路径科学合理,总收率可达62%。 1. The whole synthesis method is simple and controllable, the reaction path is scientific and reasonable, and the total yield can reach 62%. the
2、对于整个合成中的第四步偶联反应,创造性地使用Ni/PPh3催化体系,使反应收率高,副产物少,选择性好,可达99%以上。 2. For the fourth step coupling reaction in the whole synthesis, the Ni/PPh 3 catalytic system is creatively used, so that the reaction yield is high, the by-products are few, and the selectivity is good, which can reach more than 99%.
3、Ni不同于其他贵金属催化剂,反应完经简单过滤就可以继续循环使用,最重要的是价廉易得, 大大节约了生产成本。 3. Ni is different from other precious metal catalysts. After the reaction, it can continue to be recycled after simple filtration. The most important thing is that it is cheap and easy to get, which greatly saves production costs. the
4、本发明涉及到的五步合成腐蚀性小,对环境友好,符合清洁生产的要求,有利于工业化生产,符合和谐社会的低碳的宗旨。 4. The five-step synthesis involved in the present invention is less corrosive, environmentally friendly, meets the requirements of clean production, is beneficial to industrial production, and meets the low-carbon purpose of a harmonious society. the
具体实施方式 Detailed ways
以下实施例用于说明本发明,但不用来限制本发明的范围。 The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. the
实施例1 Example 1
(1) (1)
在2升的反应器中加入0.8升的无水四氢呋喃和143g的镁粉,500g的环酮原料和895g的3-氯丙基-叔丁基醚,将0.4升的无水乙醚分半小时滴加到反应器中,保持体系微沸状态,滴加完毕向体系中通入氩气,继续回流2h。反应完毕将体系冷却后倒入饱和氯化铵溶液中,加乙酸乙酯萃取三次,用无水硫酸钠干燥5h,得到的粗产品用石油醚重结晶得到产品698g,HPLC纯度分析>99%,收率90%。产品分子式:C21H26O3,分子量:326.43。熔点:124-126°C,LC-MS:326.46,元素分析:C 77.27%,H 8.03%,O 14.70%。 Add 0.8 liters of anhydrous tetrahydrofuran and 143 g of magnesium powder, 500 g of cyclic ketone raw materials and 895 g of 3-chloropropyl-tert-butyl ether into a 2-liter reactor, and drop 0.4 liters of anhydrous ether in half an hour Add it to the reactor and keep the system in a slightly boiling state. After the dropwise addition, argon gas is introduced into the system, and the reflux continues for 2 hours. After the reaction was completed, the system was cooled and poured into saturated ammonium chloride solution, extracted three times with ethyl acetate, dried with anhydrous sodium sulfate for 5 hours, and the obtained crude product was recrystallized with petroleum ether to obtain 698 g of the product, and the HPLC purity analysis was >99%. The yield is 90%. Product molecular formula: C 21 H 26 O 3 , molecular weight: 326.43. Melting point: 124-126°C, LC-MS: 326.46, elemental analysis: C 77.27%, H 8.03%, O 14.70%.
(2) (2)
在2升的耐压釜中加入上步反应得到的产品690g,再加入浓盐酸1500g,密闭耐压釜加热至沸腾,控制体系压力表为3MPa,反应5h。反应完毕冷却,蒸掉多余的溶剂,得到的粗产品用石油醚重结晶得到产品619g,HPLC纯度分析>98%,收率95%,产品分子式:C21H24O2,分子量:308.41。熔点:112-114°C,LC-MS:308.48,元素分析:C 81.78%,H 7.84%,O 10.78%。 In a 2-liter autoclave, add 690 g of the product obtained in the previous step reaction, then add 1500 g of concentrated hydrochloric acid, heat the airtight autoclave to boiling, control the system pressure gauge to 3 MPa, and react for 5 hours. After the reaction was completed and cooled, the excess solvent was distilled off, and the obtained crude product was recrystallized with petroleum ether to obtain 619g of the product. The HPLC purity analysis was >98%, and the yield was 95%. The product molecular formula: C 21 H 24 O 2 , molecular weight: 308.41. Melting point: 112-114°C, LC-MS: 308.48, elemental analysis: C 81.78%, H 7.84%, O 10.78%.
(3) (3)
在2升的耐压釜中加入上步反应得到的产品615g及0.8升的苯,将283g的 二氯亚砜溶于0.4升的苯,在室温条件下分一小时滴加到耐压釜中,滴加完毕将耐压釜密闭加热至回流,反应2h。反应完毕加乙酸乙酯萃取三次,用无水硫酸钠干燥5h,得到的粗产品用石油醚重结晶得到产品431g,HPLC纯度分析>99%,收率80%,产品分子式:C17H15ClO,分子量:270.75。熔点:107-110°C,LC-MS:270.80,元素分析:C 75.41%,H 5.58%,Cl 13.09%,O 5.91%。 Add 615g of the product obtained in the previous reaction and 0.8 liter of benzene into a 2-liter autoclave, dissolve 283 g of thionyl chloride in 0.4 liter of benzene, and add it dropwise to the autoclave in one hour at room temperature After the dropwise addition, the autoclave was sealed and heated to reflux for 2 hours. After the reaction was completed, extract with ethyl acetate three times, dry with anhydrous sodium sulfate for 5 hours, and recrystallize the obtained crude product with petroleum ether to obtain 431g of the product, HPLC purity analysis >99%, yield 80%, product molecular formula: C 17 H 15 ClO ,Molecular weight: 270.75. Melting point: 107-110°C, LC-MS: 270.80, elemental analysis: C 75.41%, H 5.58%, Cl 13.09%, O 5.91%.
(4) (4)
在2升的反应器中加入上步反应得到的产品430g及1.2升的DMF作溶剂,再加入79g N,N-二甲基甲胺,两当量的碳酸钾,再分别加入5%的Ni(OAc)2和10%的PPh3,于40°C条件下反应5h。反应完毕加乙酸乙酯萃取三次,用无水硫酸钠干燥5h,得到的粗产品用石油醚重结晶即得到产品多塞平435g,HPLC纯度分析>99%,收率98%。产品分子式:C19H21NO,分子量:279.38。熔点:182-184°C,LC-MS:279.30,元素分析:C 81.68%,H 7.58%,N 5.01%,O 5.73%。 In 2 liters of reactors, add the product 430g that last step reaction obtains and 1.2 liters of DMF as solvent, then add 79g N,N-dimethylmethylamine, two equivalents of salt of wormwood, then add 5% Ni ( OAc) 2 and 10% PPh 3 were reacted at 40°C for 5h. After the reaction was completed, ethyl acetate was added to extract three times, and dried with anhydrous sodium sulfate for 5 hours. The obtained crude product was recrystallized with petroleum ether to obtain 435 g of product doxepin. The HPLC purity analysis was >99%, and the yield was 98%. Product molecular formula: C 19 H 21 NO, molecular weight: 279.38. Melting point: 182-184°C, LC-MS: 279.30, elemental analysis: C 81.68%, H 7.58%, N 5.01%, O 5.73%.
(5) (5)
在2升的耐压釜中加入上步反应得到的产品430g,再加入浓盐酸900g,密闭耐压釜加热至140°C,控制体系压力表为3MPa,反应1 5h。反应完毕冷却至室温经过滤、干燥得到产品422g,HPLC纯度分析>98%,收率87%。产品分子式:C19H22ClNO,分子量:315.84。LC-MS:315.80,元素分析:C 72.25%,H 7.02%,Cl 11.23%,N 4.43%,O 5.07%。 In a 2-liter autoclave, add 430 g of the product obtained by the reaction in the previous step, then add 900 g of concentrated hydrochloric acid, heat the airtight autoclave to 140 ° C, control the system pressure gauge to 3 MPa, and react for 1 to 5 hours. After completion of the reaction, cool to room temperature, filter, and dry to obtain 422 g of the product, with a purity analysis of >98% by HPLC and a yield of 87%. Product molecular formula: C 19 H 22 ClNO, molecular weight: 315.84. LC-MS: 315.80, elemental analysis: C 72.25%, H 7.02%, Cl 11.23%, N 4.43%, O 5.07%.
实施例2 Example 2
(1) (1)
在4升的反应器中加入2升的无水四氢呋喃和280g的镁粉,1Kg的环酮原料和1.9Kg的3-氯丙基-叔丁基醚,将1升的无水乙醚分半小时滴加到反应器中,保持体系微沸状态,滴加完毕向体系中通入氩气,继续回流2h。反应完毕将体系冷却后倒入饱和氯化铵溶液中,加乙酸乙酯萃取三次,用无水硫酸钠干燥5h,得到的粗产品用石油醚重结晶得到产品1.42Kg,HPLC纯度分析>99%,收率88%。产品分子式:C21H26O3,分子量:326.43。熔点:124-126°C,LC-MS:326.46,元素分析:C 77.27%,H 8.03%,O 14.70%。 Add 2 liters of anhydrous tetrahydrofuran and 280g of magnesium powder, 1Kg of cyclic ketone raw material and 1.9Kg of 3-chloropropyl-tert-butyl ether into a 4-liter reactor, and divide 1 liter of anhydrous ether for half an hour Add it dropwise into the reactor, keep the system in a slightly boiling state, after the dropwise addition, feed argon into the system, and continue to reflux for 2h. After the reaction was completed, the system was cooled and poured into a saturated ammonium chloride solution, extracted three times with ethyl acetate, dried with anhydrous sodium sulfate for 5 hours, and the obtained crude product was recrystallized with petroleum ether to obtain a product of 1.42Kg, HPLC purity analysis >99% , yield 88%. Product molecular formula: C 21 H 26 O 3 , molecular weight: 326.43. Melting point: 124-126°C, LC-MS: 326.46, elemental analysis: C 77.27%, H 8.03%, O 14.70%.
(2) (2)
在4升的耐压釜中加入上步反应得到的产品1.4Kg,再加入浓盐酸3Kg,密闭耐压釜加热至沸腾,控制体系压力表为3MPa,反应5h。反应完毕冷却,蒸掉多余的溶剂,得到的粗产品用石油醚重结晶得到产品1.21Kg,HPLC纯度分析>98%,收率93%,产品分子式:C21H24O2,分子量:308.41。熔点:112-114°C,LC-MS:308.48,元素分析:C 81.78%,H 7.84%,O 10.78%。 Add 1.4Kg of the product obtained in the previous step reaction into a 4-liter autoclave, then add 3Kg of concentrated hydrochloric acid, heat the airtight autoclave to boiling, control the system pressure gauge to 3MPa, and react for 5h. After the reaction was completed and cooled, the excess solvent was distilled off, and the obtained crude product was recrystallized with petroleum ether to obtain 1.21Kg of the product. The HPLC purity analysis was >98%, and the yield was 93%. The product molecular formula: C 21 H 24 O 2 , molecular weight: 308.41. Melting point: 112-114°C, LC-MS: 308.48, elemental analysis: C 81.78%, H 7.84%, O 10.78%.
(3) (3)
在4升的耐压釜中加入上步反应得到的产品1.2Kg及1.6升的苯,将0.56Kg的二氯亚砜溶于0.8升的苯,在室温条件下分一小时滴加到耐压釜中,滴加完毕将耐压釜密闭加热至回流,反应2h。反应完毕加乙酸乙酯萃取三次,用无水硫酸钠干燥5h,得到的粗产品用石油醚重结晶得到产品0.86Kg,HPLC纯度分析>99%,收率79%,产品分子式:C17H15ClO,分子量:270.75。熔点:107-110°C,LC-MS:270.80,元素分析:C 75.41%,H 5.58%,Cl 13.09%,O 5.91%。 Add 1.2Kg of the product obtained in the previous step reaction and 1.6 liters of benzene into a 4-liter autoclave, dissolve 0.56 Kg of thionyl chloride in 0.8 liters of benzene, and add it dropwise to the pressure-resistant pot in one hour at room temperature. In the kettle, after the dropwise addition, the autoclave was sealed and heated to reflux, and reacted for 2 hours. After the reaction was completed, extract with ethyl acetate three times, dry with anhydrous sodium sulfate for 5 hours, and recrystallize the obtained crude product with petroleum ether to obtain the product 0.86Kg, HPLC purity analysis>99%, yield 79%, product molecular formula: C 17 H 15 ClO, molecular weight: 270.75. Melting point: 107-110°C, LC-MS: 270.80, elemental analysis: C 75.41%, H 5.58%, Cl 13.09%, O 5.91%.
(4) (4)
在4升的反应器中加入上步反应得到的产品0.85Kg及2.5升的DMF作溶剂,再加入160g N,N-二甲基甲胺,两当量的碳酸钾,再分别加入5%的Ni(OAc)2和10%的PPh3,于40°C条件下反应5h。反应完毕加乙酸乙酯萃取三次,用无水硫酸钠干燥5h,得到的粗产品用石油醚重结晶即得到产品多塞平0.85Kg,HPLC纯度分析>99%,收率96%。产品分子式:C19H21NO,分子量:279.38。熔点:182-184℃,LC-MS:279.30,元素分析:C 81.68%,H 7.58%,N 5.01%,O 5.73%。 Add 0.85Kg of the product obtained in the previous step reaction and 2.5 liters of DMF into a 4-liter reactor as a solvent, then add 160g N,N-dimethylmethylamine, two equivalents of potassium carbonate, and then add 5% Ni (OAc) 2 and 10% PPh 3 were reacted at 40°C for 5h. After the reaction was completed, ethyl acetate was added to extract three times, and dried with anhydrous sodium sulfate for 5 hours. The obtained crude product was recrystallized with petroleum ether to obtain the product doxepin 0.85Kg. The purity analysis by HPLC was >99%, and the yield was 96%. Product molecular formula: C 19 H 21 NO, molecular weight: 279.38. Melting point: 182-184°C, LC-MS: 279.30, elemental analysis: C 81.68%, H 7.58%, N 5.01%, O 5.73%.
(5) (5)
在4升的耐压釜中加入上步反应得到的产品0.85Kg,再加入浓盐酸1.8Kg,密闭耐压釜加热至140℃,控制体系压力表为3MPa,反应15h。反应完毕冷却至室温经过滤、干燥得到产品0.84Kg,HPLC纯度分析>98%,收率85%。产品分子式:C19H22ClNO,分子量:315.84。LC-MS:315.80,元素分析:C 72.25%,H 7.02%,Cl 11.23%,N 4.43%,O 5.07%。 Add 0.85Kg of the product obtained in the previous step into a 4-liter autoclave, then add 1.8Kg of concentrated hydrochloric acid, heat the closed autoclave to 140°C, control the system pressure gauge to 3MPa, and react for 15 hours. After the reaction was completed, cooled to room temperature, filtered and dried to obtain 0.84Kg of the product, the HPLC purity analysis was >98%, and the yield was 85%. Product molecular formula: C 19 H 22 ClNO, molecular weight: 315.84. LC-MS: 315.80, elemental analysis: C 72.25%, H 7.02%, Cl 11.23%, N 4.43%, O 5.07%.
实施例3 Example 3
与实施例1相比,本实施例的区别仅在于: Compared with embodiment 1, the difference of this embodiment only lies in:
步骤1为:用量比为1:1.2的6,11-二氢二苯并[b,e]噁庚英-11-酮和3-氯丙基-叔丁基醚在催化剂的作用下在无水乙醚中进行加成反应,反应回流得醇类化合物。其中,无水乙醚作为溶剂滴加,其体积用量为6,11-二氢二苯并[b,e]噁庚英-11-酮重量的5.8倍,其滴加速度为其用量的5%每分钟,所述的催化剂为镁粉,镁粉的投放量为6,11-二氢二苯并[b,e]噁庚英-11-酮的2倍,反应时间为3h,温度为38℃。 Step 1 is: 6,11-dihydrodibenzo[b,e]oxepin-11-one and 3-chloropropyl-tert-butyl ether with a molar ratio of 1:1.2 in the absence of catalyst Addition reaction was carried out in water and ether, and the reaction was refluxed to obtain alcohol compounds. Wherein, anhydrous diethyl ether is added dropwise as a solvent, and its volumetric dosage is 5.8 times the weight of 6,11-dihydrodibenzo[b,e]oxepin-11-one, and its dropping speed is 5% of its dosage per minutes, the catalyst is magnesium powder, the dosage of magnesium powder is twice that of 6,11-dihydrodibenzo[b,e]oxepin-11-one, the reaction time is 3h, and the temperature is 38°C . the
步骤2中醇类化合物在浓盐酸条件下保持沸腾,浓盐酸的用量为反应底物的6倍;反应时间为6h。 In step 2, the alcohol compound is kept boiling under the condition of concentrated hydrochloric acid, and the amount of concentrated hydrochloric acid is 6 times that of the reaction substrate; the reaction time is 6 hours. the
步骤3中反应溶剂为苯,烯烃类化合物与二氯亚砜的用量比为1:1.2,反应在115℃下加热回流3h。 In step 3, the reaction solvent is benzene, the ratio of olefinic compound to thionyl chloride is 1:1.2, and the reaction is heated to reflux at 115° C. for 3 h. the
步骤4具体为:在催化剂的作用下,氯代物和N,N-二甲基甲胺在DMF于40°C条件下反应5h,偶联得到多塞平。其中,氯代物和N,N-二甲基甲胺的用量比为1:1.1,催化剂的投放量为5%,配体与氯代物的用量比为10:1。 Step 4 is specifically: under the action of a catalyst, the chloride and N,N-dimethylmethylamine are reacted in DMF at 40° C. for 5 h, and doxepin is obtained through coupling. Among them, the dosage ratio of chloride and N,N-dimethylmethylamine is 1:1.1, the dosage of catalyst is 5%, and the ratio of ligand to chloride is 10:1. the
步骤5为:多塞平在浓盐酸中,以140℃反应16h得到盐酸多塞平,多塞平与浓盐酸的用量比为1:5。 Step 5 is: react doxepin in concentrated hydrochloric acid at 140° C. for 16 hours to obtain doxepin hydrochloride, and the dosage ratio of doxepin to concentrated hydrochloric acid is 1:5. the
本实施例所得盐酸多塞平的纯度为98%,总收率为62%。 The purity of doxepin hydrochloride obtained in this example was 98%, and the total yield was 62%. the
实施例4 Example 4
与实施例1相比,本实施例的区别仅在于:步骤1为:用量比为1:1的6,11-二氢二苯并[b,e]噁庚英-11-酮和3-氯丙基-叔丁基醚在催化剂的作用下在无水乙醚中进行加成反应,反应回流得醇类化合物。其中,无水乙醚其体积用量为6,11-二氢二苯并[b,e]噁庚英-11-酮重量的5.5倍,其滴加速度为其用量的2%每分钟。所述的催化剂为镁粉,镁粉的投放量为6,11-二氢二苯并[b,e]噁庚英-11-酮的1.8倍,反应时间为2h,温度为35℃。 Compared with Example 1, the difference of this example is only that: Step 1 is: 6,11-dihydrodibenzo[b,e]oxepin-11-one and 3- Chloropropyl-tert-butyl ether undergoes an addition reaction in anhydrous ether under the action of a catalyst, and the reaction is refluxed to obtain alcohol compounds. Among them, the volumetric dosage of anhydrous diethyl ether is 5.5 times the weight of 6,11-dihydrodibenzo[b,e]oxepin-11-one, and its dropping rate is 2% of its dosage per minute. The catalyst is magnesium powder, the dosage of magnesium powder is 1.8 times that of 6,11-dihydrodibenzo[b,e]oxepin-11-one, the reaction time is 2 hours, and the temperature is 35°C. the
步骤2中醇类化合物在浓盐酸条件下保持沸腾,浓盐酸的用量为反应底物的2倍;反应时间为5h。 In step 2, the alcohol compound is kept boiling under the condition of concentrated hydrochloric acid, and the amount of concentrated hydrochloric acid is twice that of the reaction substrate; the reaction time is 5 hours. the
步骤3中反应溶剂为甲苯,烯烃类化合物与二氯亚砜的用量比为1:1,反应在110℃下加热回流2h。 In step 3, the reaction solvent is toluene, the ratio of olefinic compound to thionyl chloride is 1:1, and the reaction is heated to reflux at 110° C. for 2 h. the
步骤4具体为:在催化剂的作用下,氯代物和N,N-二甲基甲胺在DMF于 35℃条件下反应4h,偶联得到多塞平。其中,氯代物和N,N-二甲基甲胺的用量比为1:1,催化剂的投放量为2%,配体与氯代物的用量比为8:1。 Step 4 is specifically: under the action of a catalyst, the chloride and N,N-dimethylmethylamine are reacted in DMF at 35°C for 4 hours, and doxepin is obtained through coupling. Among them, the dosage ratio of chloride and N,N-dimethylmethylamine is 1:1, the dosage of catalyst is 2%, and the ratio of ligand to chloride is 8:1. the
步骤5为:多塞平在浓盐酸中,以135℃反应15h得到盐酸多塞平,多塞平与浓盐酸的用量比为1:4。 Step 5 is: react doxepin in concentrated hydrochloric acid at 135° C. for 15 hours to obtain doxepin hydrochloride, and the dosage ratio of doxepin to concentrated hydrochloric acid is 1:4. the
本实施例所得盐酸多塞平的纯度为99%,总收率为60%。 The purity of doxepin hydrochloride obtained in this example was 99%, and the total yield was 60%. the
实施例5 Example 5
与实施例1相比,本实施例的区别仅在于:步骤1为:用量比为1:1.5的6,11-二氢二苯并[b,e]噁庚英-11-酮和3-氯丙基-叔丁基醚在催化剂的作用下在无水乙醚中进行加成反应,反应回流得醇类化合物。其中,无水乙醚其体积用量为6,11-二氢二苯并[b,e]噁庚英-11-酮重量的6.3倍,其滴加速度为其用量的6%每分钟。所述的催化剂为镁粉,镁粉的投放量为6,11-二氢二苯并[b,e]噁庚英-11-酮的2.2倍,反应时间为5h,温度为40℃。 Compared with Example 1, the difference of this example is only that: Step 1 is: 6,11-dihydrodibenzo[b,e]oxepin-11-one and 3- Chloropropyl-tert-butyl ether undergoes an addition reaction in anhydrous ether under the action of a catalyst, and the reaction is refluxed to obtain alcohol compounds. Among them, the volumetric dosage of anhydrous diethyl ether is 6.3 times the weight of 6,11-dihydrodibenzo[b,e]oxepin-11-one, and its dropping rate is 6% of its dosage per minute. The catalyst is magnesium powder, the dosage of magnesium powder is 2.2 times that of 6,11-dihydrodibenzo[b,e]oxepin-11-one, the reaction time is 5 hours, and the temperature is 40°C. the
步骤2中醇类化合物在浓盐酸条件下保持沸腾,浓盐酸的用量为反应底物的10倍;反应时间为8h。 In step 2, the alcohol compound is kept boiling under the condition of concentrated hydrochloric acid, the amount of concentrated hydrochloric acid is 10 times that of the reaction substrate; the reaction time is 8h. the
步骤3中反应溶剂为甲苯,烯烃类化合物与二氯亚砜的用量比为1:1.5,反应在120℃下加热回流4h。 In step 3, the reaction solvent is toluene, the ratio of olefinic compound to thionyl chloride is 1:1.5, and the reaction is heated to reflux at 120° C. for 4 h. the
步骤4具体为:在催化剂的作用下,氯代物和N,N-二甲基甲胺在DMF于45℃条件下反应6h,偶联得到多塞平。其中,氯代物和N,N-二甲基甲胺的用量比为1:1.5,催化剂的投放量为8%,配体与氯代物的用量比为12:1。 Step 4 is specifically: under the action of a catalyst, the chloride and N,N-dimethylmethylamine are reacted in DMF at 45° C. for 6 hours, and doxepin is obtained through coupling. Among them, the dosage ratio of chloride to N,N-dimethylmethylamine is 1:1.5, the dosage of catalyst is 8%, and the ratio of ligand to chloride is 12:1. the
步骤5为:多塞平在浓盐酸中,以145℃反应18h得到盐酸多塞平,多塞平与浓盐酸的用量比为1:6。 Step 5 is: react doxepin in concentrated hydrochloric acid at 145° C. for 18 hours to obtain doxepin hydrochloride, and the dosage ratio of doxepin to concentrated hydrochloric acid is 1:6. the
本实施例所得盐酸多塞平的纯度为98%,总收率为62%。 The purity of doxepin hydrochloride obtained in this example was 98%, and the total yield was 62%. the
实施例6 Example 6
与实施例1相比,本实施例的区别仅在于:步骤1为:用量比为1:1.3的6,11-二氢二苯并[b,e]噁庚英-11-酮和3-氯丙基-叔丁基醚在催化剂的作用下在无水乙醚中进行加成反应,反应回流得醇类化合物。其中,无水乙醚其体积用量为6,11-二氢二苯并[b,e]噁庚英-11-酮重量的5.9倍,所述的催化剂为镁粉,镁粉的投放量为6,11-二氢二苯并[b,e]噁庚英-11-酮的1.9倍,反应时间为2-5h,温度为35-40℃。 Compared with Example 1, the difference of this example is only that: Step 1 is: 6,11-dihydrodibenzo[b,e]oxepin-11-one and 3- Chloropropyl-tert-butyl ether undergoes an addition reaction in anhydrous ether under the action of a catalyst, and the reaction is refluxed to obtain alcohol compounds. Wherein, its volume consumption of anhydrous diethyl ether is 5.9 times of 6,11-dihydrodibenzo[b,e]oxepin-11-one weight, and described catalyst is magnesium powder, and the dosage of magnesium powder is 6 , 1.9 times that of 11-dihydrodibenzo[b,e]oxepin-11-one, the reaction time is 2-5h, and the temperature is 35-40℃. the
步骤2中醇类化合物在浓盐酸条件下保持沸腾,浓盐酸的用量为反应底物的5倍;反应时间为6h。 In step 2, the alcohol compound is kept boiling under the condition of concentrated hydrochloric acid, and the amount of concentrated hydrochloric acid is 5 times that of the reaction substrate; the reaction time is 6 hours. the
步骤3中反应溶剂为苯,烯烃类化合物与二氯亚砜的用量比为1:1.3,反应在115℃下加热回流3h。 In step 3, the reaction solvent is benzene, the ratio of olefinic compound to thionyl chloride is 1:1.3, and the reaction is heated to reflux at 115° C. for 3 h. the
步骤4具体为:在催化剂的作用下,氯代物和N,N-二甲基甲胺在DMF于42°C条件下反应6h,偶联得到多塞平。其中,氯代物和N,N-二甲基甲胺的用量比为1:1.3,催化剂的投放量为5%,配体与氯代物的用量比为8:1。 Step 4 is specifically: under the action of a catalyst, react the chloride and N,N-dimethylmethylamine in DMF at 42°C for 6 hours, and couple to obtain doxepin. Among them, the dosage ratio of chloride and N,N-dimethylmethylamine is 1:1.3, the dosage of catalyst is 5%, and the ratio of ligand to chloride is 8:1. the
步骤5为:多塞平在浓盐酸中,以142℃反应17h得到盐酸多塞平,多塞平与浓盐酸的用量比为1:5。 Step 5 is: react doxepin in concentrated hydrochloric acid at 142° C. for 17 hours to obtain doxepin hydrochloride, and the dosage ratio of doxepin to concentrated hydrochloric acid is 1:5. the
本实施例所得盐酸多塞平的纯度为99%,总收率为62%。 The purity of doxepin hydrochloride obtained in this example was 99%, and the total yield was 62%. the
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。 Although, the present invention has been described in detail with general description, specific implementation and test above, but on the basis of the present invention, some modifications or improvements can be made to it, which will be obvious to those skilled in the art . Therefore, the modifications or improvements made on the basis of not departing from the spirit of the present invention all belong to the protection scope of the present invention. the
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210388828.XA CN102924424B (en) | 2012-09-04 | 2012-10-15 | Method for synthesizing doxepin hydrochloride |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210322830 | 2012-09-04 | ||
| CN201210322830.7 | 2012-09-04 | ||
| CN201210388828.XA CN102924424B (en) | 2012-09-04 | 2012-10-15 | Method for synthesizing doxepin hydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102924424A CN102924424A (en) | 2013-02-13 |
| CN102924424B true CN102924424B (en) | 2014-09-03 |
Family
ID=47639383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210388828.XA Active CN102924424B (en) | 2012-09-04 | 2012-10-15 | Method for synthesizing doxepin hydrochloride |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102924424B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105085464A (en) * | 2015-08-17 | 2015-11-25 | 苏州统华药品有限公司 | Synthesis method of doxepin hydrochloride |
| CN105061386A (en) * | 2015-08-17 | 2015-11-18 | 苏州黄河制药有限公司 | Method for synthesizing doxepin hydrochloride by utilizing phthalic anhydride as raw material |
| CN105085465A (en) * | 2015-08-17 | 2015-11-25 | 苏州黄河制药有限公司 | Method for synthesizing doxepin hydrochloride by taking halomethyl o-toluate as raw material |
| CN105111181A (en) * | 2015-08-17 | 2015-12-02 | 苏州黄河制药有限公司 | Synthetic method of doxepin hydrochloride using methylbenzoate as raw materials |
| CN105330638A (en) * | 2015-11-26 | 2016-02-17 | 苏州黄河制药有限公司 | Method for synthesizing doxepin hydrochloride by utilizing o-toluic acid as raw material |
| CN105367538A (en) * | 2015-11-26 | 2016-03-02 | 苏州黄河制药有限公司 | Method for preparing doxepin hydrochloride using o-halogen methyl methyl benzoate as raw material |
| CN111790443B (en) * | 2020-07-17 | 2022-11-04 | 万华化学集团股份有限公司 | A supported catalyst and its preparation method and application |
| CN116239562B (en) * | 2021-12-07 | 2024-12-31 | 江苏师范大学 | A method for synthesizing doxepin hydrochloride using benzofuranone as raw material |
| CN115124500B (en) * | 2022-08-08 | 2024-01-30 | 苏州弘森药业股份有限公司 | Method for refining doxepin |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090042971A1 (en) * | 2006-05-19 | 2009-02-12 | Somaxon Pharmaceuticals, Inc. | Method of using low-dose doxepin for the improvement of sleep |
| US20100179215A1 (en) * | 2006-05-19 | 2010-07-15 | Somaxon Pharmaceuticals, Inc. | Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders |
-
2012
- 2012-10-15 CN CN201210388828.XA patent/CN102924424B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090042971A1 (en) * | 2006-05-19 | 2009-02-12 | Somaxon Pharmaceuticals, Inc. | Method of using low-dose doxepin for the improvement of sleep |
| US20100179215A1 (en) * | 2006-05-19 | 2010-07-15 | Somaxon Pharmaceuticals, Inc. | Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102924424A (en) | 2013-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102924424B (en) | Method for synthesizing doxepin hydrochloride | |
| CN102690224A (en) | Preparation method for 3-(4- chlorobutyl)-1H-5-cyanoindole as a vilazodone intermediate | |
| CN102229613A (en) | New process for synthesis of asenapine | |
| CN102108070A (en) | Preparation methods of 5-aminobenzofuran-2-formate and intermediate thereof | |
| JP5873484B2 (en) | Dronedarone and method for producing the salt thereof | |
| CN103420908A (en) | Preparation method of montelukast chiral intermediate | |
| CN102070596A (en) | Preparation method for dihydrosafrole | |
| CN103183680A (en) | Method for preparing asenapine | |
| CN107602399A (en) | A kind of preparation method of enkephalinase inhibitor intermediate | |
| CN102731326A (en) | Synthetic method of (S)-amino-5-methoxy-1, 2, 3, 4-tetrahydronaphthalene hydrochloride | |
| CN104478918A (en) | Synthesis method of cycloalkene-1-boronic acid pinacol ester | |
| CN101723897A (en) | Method for synthesizing Ivabradine | |
| CN102807516A (en) | Intermediate in amisulpride and method for preparing amisulpride by using intermediate | |
| CN105085158A (en) | Synthesis method of methyl benzotrifluoride | |
| CN116987034A (en) | 5-((4-chloro-2,3-dihydro-1H-inden-1-yl)methyl)-1H-imidazole and its synthesis method | |
| CN105601495B (en) | It is a kind of how the synthetic method of the smooth intermediate of appropriate pyrrole | |
| CN102936205B (en) | Synthesis method of tapentadol | |
| CN101265201B (en) | A kind of synthetic method of tramadol hydrochloride | |
| CN111039860B (en) | Synthetic method and application of 2-hydroxy-N- (4' -chlorobiphenyl-2-yl) nicotinamide | |
| CN102964271B (en) | Synthesis method of sartan anti-hypertensive medicament intermediate 2-cyan-4'-methyl diphenyl | |
| JP5911468B2 (en) | Process for producing asymmetric secondary tert-butylamine in gas phase | |
| CN108047032A (en) | By α-ketoglutaric acid to glutaric acid synthetic method | |
| CN102372642B (en) | Preparation method of (1S)-4,5-dimethoxy-1-((methyl amino) methyl) benzo cyclobutane | |
| CN111087357B (en) | Preparation method of Prisamod | |
| CN101134740A (en) | A kind of synthetic method of key intermediate benzoylpyrrole of ketorolac tromethamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: GCL Petrochemical District of Taicang Port Development Zone Taicang Road, Suzhou City, Jiangsu Province, No. 12 215433 Patentee after: SUZHOU HOMESUN PHARMACEUTICAL CO.,LTD. Address before: GCL Petrochemical District of Taicang Port Development Zone Taicang Road, Suzhou City, Jiangsu Province, No. 12 215433 Patentee before: SUZHOU HOMESUN PHARMACEUTICAL Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for synthesizing doxepin hydrochloride Granted publication date: 20140903 Pledgee: Bank of China Limited Taicang Branch Pledgor: SUZHOU HOMESUN PHARMACEUTICAL CO.,LTD. Registration number: Y2024980055357 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |